Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avalyn PharmaAVLN -1.01%11 Forward PE Ratio is 0.00 as of Aug. 03, 2026. GuruFocus rates AVLN with a GF Score™ of 11/100. Among 354 Biotechnology companies, Avalyn Pharma ranks worse than 282485.59% on this metric.
Avalyn Pharma (NAS:AVLN) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Avalyn Pharma Forward PE Ratio Related Terms
Avalyn Pharma Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Avalyn Pharma's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalyn Pharma Forward PE Ratio Chart
Avalyn Pharma Annual Data
Trend
Forward PE Ratio
Avalyn Pharma Semi-Annual Data
Forward PE Ratio
AVLN vs TRAX, IMTX, ARDX: Forward PE Ratio Comparison
For the Biotechnology subindustry, Avalyn Pharma's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avalyn Pharma Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avalyn Pharma's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Avalyn Pharma's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Avalyn Pharma (AVLN) has a Forward PE Ratio of 0.00 as of Aug. 03, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Avalyn Pharma and its competitors. According to the industry distribution chart, Avalyn Pharma ranks #999999 out of 354 companies in the Biotechnology industry.
Is Avalyn Pharma's Forward PE Ratio too high?
Avalyn Pharma's current Forward PE Ratio is 0.00. Based on the distribution chart, Avalyn Pharma ranks #999999 out of 354 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Avalyn Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Avalyn Pharma's Forward PE Ratio compare to TRAX and IMTX?
According to the Biotechnology industry distribution chart, Avalyn Pharma ranks #999999 out of 354 companies for Forward PE Ratio. This places Avalyn Pharma in the lower half of its industry. The industry median Forward PE Ratio is 22.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.10, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Avalyn Pharma and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avalyn Pharma's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalyn Pharma stock overvalued right now?
Avalyn Pharma (AVLN) has a current Forward PE Ratio of 0.00. The current Forward PE Ratio is 0.00. Avalyn Pharma's overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Avalyn Pharma (AVLN), the current Forward PE Ratio is 0.00 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
11GF Score
Get the complete analysis for AVLN
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVLN has been successfully added to your 
